CinRx Pharma is a mosaic of biotechnology companies supported by a dedicated funding mechanism designed to improve drug development success by accelerating promising new medicines to patients. Integrating our pre-clinical, clinical and operational expertise with multiple shots on goal, we customize the optimal development trajectory for each pipeline candidate – a drug development superhighway. Our team ensures high-potential medicines are financially and operationally championed with the most efficient route from the lab to the patient.
CinRx’s leadership team are experts in the planning and execution of the drug development process. Our range of cross-functional expertise gained through decades of treating patients, coupled with real-word experiences across numerous therapeutic areas ensures the optimal path for drug development.
Jon Isaacsohn (MD, FACC)
Founder & Chief Executive Officer
Gavin Samuels (MD, MBA)
Chief Business Officer
Board of Directors
Dr. Jon Isaacsohn has served as Chief Executive Officer of CinRx Pharma since co-founding the company in 2015 and serves as a member of the company’s Board of Directors. Jon also served as founding Chief Executive Officer of a CinRx portfolio company, CinCor Pharma. He continues to serve as the Chief Executive Officer of CinRx’s other portfolio companies, including CinDome, CinSano, and CinFina.
Prior to co-founding CinRx Pharma in 2015, Dr. Isaacsohn served as Chief Medical Officer for Teva Pharmaceuticals where he was responsible for developing Teva’s Specialty Drugs and overseeing the New Therapeutic Entities (NTEs) initiative across all therapeutic areas. He was Executive Vice President, Head of Medical & Regulatory Affairs at Medpace, a global leader in research-based drug development for nearly 15 years. Jon was a co-founder of the Metabolic & Atherosclerosis Research Center in Cincinnati, OH.
During his career, Dr. Isaacsohn has been involved in developing numerous drugs from early phases through global submissions in various therapeutic areas. He trained in Internal Medicine and Cardiology at Harvard Medical School and was a member of the cardiology faculty at Yale Medical School.
Dr. Brian Murphy is a board-certified in infectious disease, internal medicine, as well as pediatrics, and brings more than 20 years of leadership in clinical trial and drug development to the CinRx team as Chief Medical Officer.
He most recently served as Senior Vice President of Medical Affairs and therapeutic lead for the Infectious Diseases franchise at Medpace. Dr. Murphy has worked with large and small biopharmaceutical companies, government agencies, public-private partnerships, and academic centers during the approval of multiple products across various therapeutic areas. In his academic career at the University of Kentucky he led multi-disciplinary, translational, and clinical research projects sponsored by NIH, CDC, Department of Defense, and pharma in a broad range of indications and patient populations at all phases of clinical development (pre-clinical through Phase IV).
Dr. Murphy received his Doctor of Medicine degree from the University of Louisville and his undergraduate diploma in biology from the University of Louisville. Dr. Murphy also received his Master of Public Heath in Epidemiology from the University of Kentucky. Dr. Murphy continues to uphold an academic appointment and maintains close ties with his clinical and research colleagues.
Mary Bond has been a critical part of CinRx since joining in 2018 and currently serves as the company’s Chief Translational Science Officer. Mary is responsible for all discovery, non-clinical, and clinical pharmacology development activities including chemistry, manufacturing and controls (CMC), across the CinRx portfolio.
Prior to joining CinRx Pharma, Mary’s experience includes roles of increasing responsibility within early development and clinical pharmacology at large pharmaceutical companies as well as a rapidly growing small to mid-size biopharmaceutical company.
Mary brings a strong understanding of the financial, strategic, regulatory, and commercial considerations necessary for successful pharmaceutical product development of small and large molecules.
Mary has a Master of Science in Microbiology from Thomas Jefferson University and a Master of Business Administration from Temple University.
Dr. Gavin Samuels assumed the role Chief Business Officer at CinRx Pharma in June 2022. Prior to this, he served as Strategic Business Advisor to CinRx since August 2021. In his role, Dr. Samuels is responsible for leading strategic, business & corporate development functions and transactions for the CinRx portfolio.
Dr. Samuels has 25 years of experience across large and emerging biotech settings in various functions including business development, private and public financing, investor relations, and strategy. Before joining CinRx, he served as Global Head of Strategy & Growth Initiatives at Lonza Biologics, where he oversaw strategic development and implementation of new business models and strategies. Prior to this, Dr. Samuels held transactional and business development positions at Merck, Pfizer and Teva Pharmaceuticals.
Dr. Samuels received a Bachelor of Medicine and Surgery (M.D.) from the University of Witwatersrand, and a Master of Business Administration from the University of New England.
Chief Administrative Officer
Sally Dressman joined CinRx in March 2022 as the company’s Chief Administrative Officer. In this role, Sally is leading the company’s strategy to optimize talent across the current & future portfolio, implementing & scaling systems, and helping CinRx to achieve our mission and goals.
Sally brings 25+ years of cross-functional leadership in the drug development space to CinRx. She has an impressive track-record of leading high-performing teams ranging from compliance, pharmacology, corporate strategy & administration, and other important clinical trial and operations functions.
Ms. Dressman has a Bachelor’s of Science in Nursing from Clemson University.
August J. Troendle, M.D. has been the Chief Executive Officer of Medpace since he founded the company in July 1992, and also was the President through July 31, 2021. Before founding Medpace, Dr. Troendle served as Assistant Director, Associate Director and Senior Associate Director from 1987 to 1992 at Sandoz (Novartis), where he was responsible for the clinical development of lipid altering agents. From 1986 to 1987, Dr. Troendle worked as a Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA. Dr. Troendle also has extensive experience serving as a director for a diverse group of public and private companies, including as a director of Coherus BioSciences, Inc. from 2012 to February 2018, as a director of Xenon Pharmaceuticals Inc. from 2007 to 2008, as a director of LIB Therapeutics, LLC since 2015, as a director of CinCor Pharma, Inc. from March 2018 to November 2021 and as a director of CinRx Pharma, LLC since 2015.
Dr. Troendle received his Medical Degree from the University of Maryland, School of Medicine and his Master of Business Administration from Boston University.
President, Medpace, Inc.
Jesse Geiger has served as the President of Medpace since August 2021. He joined Medpace in October 2007 as Corporate Controller, and he was appointed Chief Financial Officer in March 2011. Mr. Geiger became Chief Operating Officer, Laboratory Operations in November 2014. Prior to joining Medpace, Mr. Geiger worked for SENCORP from 2004 to 2007 as the Corporate Controller and Manager of Financial Planning and Analysis. Prior to SENCORP, Mr. Geiger served as the Director of Capital Markets for Cincinnati Bell from 2002 to 2004. Mr. Geiger started his career in the audit practice at Arthur Andersen LLP. Mr. Geiger has served as a director for several private companies, including as a director of LIB Therapeutics, LLC since 2015 and as a director of CinRx Pharma, LLC since 2015.
Mr. Geiger received his Bachelor of Business Administration in Accounting from the University of Cincinnati and is a Certified Public Accountant (Inactive).
Stephen P. Ewald joined Medpace as General Counsel, Chief Compliance Officer & Corporate Secretary in June 2012. Prior to joining Medpace, Mr. Ewald served as the Managing Director and Chief Legal Officer of Brevet Capital Management from May 2011 to June 2012. From May 2009 to May 2011, he was a Managing Director and Assistant General Counsel for Cantor Fitzgerald Securities/Cantor Fitzgerald & Co. Mr. Ewald was employed with Bank of America from 1999 to 2009, serving in various roles within the legal department and the Global Markets Group, including Managing Director and Chief Operating Officer of the Principal Capital Group, a proprietary investing group within Bank of America Securities. Mr. Ewald has served as director for several private companies, including as director of LIB Therapeutics, LLC since 2016 and as a director of CinRx Pharma, LLC since 2016. Mr. Ewald has also served on the Board for Mercy Health Foundation since 2015 and as Chairman of the Board since 2017.
Mr. Ewald received his Bachelor of Science in Political Sciences from the University of Cincinnati and his Juris Doctorate from the University of Cincinnati College of Law.